Scarica l'app Stockscreener
0.7607
3.41%
0.0251
Dopo l'orario di chiusura:
.74
-0.0207
-2.72%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7356
Aprire:
$0.767
Volume 24 ore:
84,795
Relative Volume:
0.03
Capitalizzazione di mercato:
$12.34M
Reddito:
$2.05M
Utile/perdita netta:
$-23.15M
Rapporto P/E:
-0.1147
EPS:
-6.6319
Flusso di cassa netto:
$-16.93M
1 W Prestazione:
+3.92%
1M Prestazione:
+6.78%
6M Prestazione:
-74.73%
1 anno Prestazione:
-67.21%
Intervallo 1D:
$0.7605
$0.767
Intervallo di 1 settimana:
$0.7159
$0.767
Portata 52W:
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Confronta IBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.7607 | 11.93M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
iBio Inc Borsa (IBIO) Ultime notizie
What analysts say about iBio Inc. stockHigh-profit trading signals - jammulinksnews.com
What drives iBio Inc. stock priceSkyrocketing profit margins - Autocar Professional
iBio Inc. Stock Analysis and ForecastFree Investment Case Studies - jammulinksnews.com
Is iBio Inc. a good long term investmentExplosive earning power - jammulinksnews.com
how ibio stock performs during market volatilityFree Short-Term Stock Picks - Newser
what makes ibio inc. stock price move sharplyFree Step-by-Step Investment Guide - Newser
What institutions are buying iBio Inc. stock nowFree Access to Investment Community - Newser
Why iBio Inc. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
What makes iBio Inc. stock price move sharplyChart Based Entries - Newser
IBIO’s Market Whiplash: -61.36% YTD Decline, -20.36% Plunge in 30 Days - investchronicle.com
How iBio Inc. stock performs during market volatilityFree Access to Investors Club - Newser
iBio (NYSEMKT:IBIO) Stock Price Down 0% – What’s Next? - Defense World
iBio stock soars after amylin receptor antibody shows promising results - Investing.com
iBio Advances Obesity Care with Antibody Therapies - TipRanks
iBio (IBIO) Reports Promising Preclinical Results in Obesity Stu - GuruFocus
US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of EarningsBlackBerry (NYSE:BB), Carnival (NYSE:CCL) - Benzinga
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agon - GuruFocus
iBio's Next-Gen Obesity Therapies: A Strategic Pipeline with Transformative Potential - AInvest
iBio Extends Promissory Note Maturity to 2026 - TipRanks
Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech
iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa
iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus
iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus
iBio initiates non-human primate study of IBIO-610 - TipRanks
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times
Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan
iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus
Sector Update: Health Care - MarketScreener
IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com
Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com
iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Plant-Based Vaccines Market Detailed In New Research Report - openPR.com
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):